Vera Therapeutics, Inc. financial data

Symbol
VERA on Nasdaq
Industry
Pharmaceutical Preparations
Location
8000 Marina Boulevard, Suite 120, Brisbane, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 10, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.08K % +48.3%
Debt-to-equity 34.2 % -0.81%
Return On Equity -52.4 % +40.7%
Return On Assets -39.1 % +40.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.7M shares +23.6%
Entity Public Float 449M USD +175%
Common Stock, Value, Issued 54K USD
Weighted Average Number of Shares Outstanding, Basic 51M shares +35.3%
Weighted Average Number of Shares Outstanding, Diluted 51M shares +35.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 76.3M USD -6.42%
General and Administrative Expense 25.5M USD +8.31%
Operating Income (Loss) -102M USD +3.11%
Nonoperating Income (Expense) 7.56M USD +144%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -96M USD -7.79%
Income Tax Expense (Benefit) 1K USD 0%
Net Income (Loss) Attributable to Parent -94.3M USD +7.58%
Earnings Per Share, Basic -2.01 USD/shares +41.6%
Earnings Per Share, Diluted -2.01 USD/shares +41.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 69.1M USD -49.7%
Marketable Securities, Current 335M USD +460%
Other Assets, Current 568K USD -35.7%
Assets, Current 416M USD +104%
Property, Plant and Equipment, Net 81K USD +80%
Operating Lease, Right-of-Use Asset 2.43M USD -47.1%
Assets 419M USD +100%
Accounts Payable, Current 5.21M USD -2.2%
Employee-related Liabilities, Current 1.28M USD +12.5%
Accrued Liabilities, Current 7.06M USD -54.8%
Liabilities, Current 14.5M USD -38.2%
Operating Lease, Liability, Noncurrent 919K USD -71.2%
Liabilities 65.8M USD +26.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -173K USD -4225%
Retained Earnings (Accumulated Deficit) -337M USD -38.8%
Stockholders' Equity Attributable to Parent 354M USD +124%
Liabilities and Equity 419M USD +100%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.8M USD -28.7%
Net Cash Provided by (Used in) Financing Activities 277M USD +156%
Net Cash Provided by (Used in) Investing Activities -219M USD -1892%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 23.4M USD -75.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 69.1M USD -49.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.52M USD -53.3%
Deferred Tax Assets, Valuation Allowance 71.4M USD +43.8%
Deferred Tax Assets, Gross 72.1M USD +42.1%
Operating Lease, Liability 3.19M USD -44.9%
Payments to Acquire Property, Plant, and Equipment 63K USD +1.61%
Lessee, Operating Lease, Liability, to be Paid 4.14M USD -42.2%
Operating Lease, Liability, Current 2.28M USD -12.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.88M USD -37.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 944K USD -30.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 27.5M USD +25.5%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) 1K USD 0%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.51M USD +60.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Operating Lease, Payments 764K USD +2.41%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 1K USD 0%
Current Federal Tax Expense (Benefit) 0 USD
Deferred Tax Assets, Net of Valuation Allowance 719K USD -33.8%
Share-based Payment Arrangement, Expense 13M USD +30.9%
Interest Expense 4.82M USD +176%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%